Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary NeuroMetrix Reports Q2 2022 Financial Results
WOBURN, Mass. , July 21, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and six months period ended June 30, 2022 . The Company's mission is to reduce the impact of neurological disorders and pain syndromes on individuals
View HTML
Toggle Summary NeuroMetrix, Inc. Announces Date for Second Quarter 2022 Financial Results Conference Call
WOBURN, Mass. , July 14, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 second quarter financial results before the opening of the market on July 21, 2022 . The Company will host a conference call at 8:00 a.m., Eastern Time on July 21, 2022
View HTML
Toggle Summary NeuroMetrix Appoints Brad Fluegel to its Board of Directors
WOBURN, Mass. , June 28, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced the appointment of Bradley M. Fluegel to its Board of Directors, effective as of July 1, 2022 . Mr. Fluegel has a broad commercial and advisory background with concentrated industry experience in
View HTML
Toggle Summary NeuroMetrix Reports that Quell® Wearable Neuromodulation Device has Received FDA De Novo Authorization as First Non-Pharmacological Treatment for Fibromyalgia
WOBURN, Mass. , May 19, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced U.S. Food and Drug Administration (FDA) De Novo authorization to market the Quell neuromodulation device as an aid for reducing the symptoms of fibromyalgia in adults with high pain sensitivity.
View HTML
Toggle Summary NeuroMetrix Reports Q1 2022 Financial Results
WOBURN, Mass. , April 26, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2022 . The Company's mission is to reduce the impact of neurological disorders and pain syndromes on individuals and on population
View HTML
Toggle Summary NeuroMetrix, Inc. Announces Date for First Quarter 2022 Financial Results Conference Call
WOBURN, Mass. , April 19, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 first quarter financial results before the opening of the market on April 26, 2022 . The Company will host a conference call at 8:00 a.m., Eastern Time on April 26,
View HTML
Toggle Summary NeuroMetrix Reports that Quell® Wearable Neuromodulator to be Evaluated in Post-Acute COVID-19 Syndrome
WOBURN, Mass. , Feb. 24, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell wearable neuromodulation technology will be evaluated for treatment of a fibromyalgia-like syndrome in individuals with post-acute COVID-19 syndrome (PACS, or "long COVID").
View HTML
Toggle Summary NeuroMetrix Reports Q4 and Full Year 2021 Financial Results
WOBURN, Mass. , Jan. 27, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2021 . The Company's mission is to reduce the impact of neurological disorders and pain syndromes on individuals and
View HTML
Toggle Summary NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2021 Financial Results Conference Call
WOBURN, Mass. , Jan. 20, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2021 fourth quarter and full year financial results before the opening of the market on January 27, 2022 . The Company will host a conference call at 8:00 a.m., Eastern Time
View HTML
Toggle Summary NeuroMetrix Receives FDA Breakthrough Device Designation for Treatment of Chronic Chemotherapy Induced Peripheral Neuropathy (CIPN) with its Wearable Neurostimulation Technology
WOBURN, Mass. , Jan. 18, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell ® technology has received Breakthrough Designation from the U.S. Food and Drug Administration (FDA) for reducing moderate to severe symptoms of chemotherapy induced peripheral
View HTML